Novo Nordisk, led by new CEO Maziar Mike Doustdar, has made a surprise move to challenge Pfizer’s ownership of Metsera, an emerging obesity biotech. The Danish pharma is offering $8.5 billion for the company, which had previously accepted nearly $5 billion from Pfizer just months ago.
Pfizer, however, seems livid and accuses Novo Nordisk of attempting to suppress competition in violation of law. The situation has sparked concerns about regulatory risks and potential long closing terms.
Doustdar’s new leadership style is seen as a radical transformation, but he also appears to be aware of the impact on employees and is actively seeking out former colleagues who may be looking for work. Novo Nordisk, which had previously struggled with declining semaglutide revenue, has been revitalized under Doustdar’s leadership.
The outcome of this bid will be critical in determining Metsera’s future with either Pfizer or Novo Nordisk. The next few business days will provide the answers to whether Doustdar can pull off a major coup and turn Novo Nordisk into a force to be reckoned with once again.
Source: https://www.biospace.com/business/editorial-novos-ceo-doesnt-seem-to-mind-being-big-pharmas-villian